Key result
Atorvastatin, simvastatin, and pravastatin improve cardiac performance and lower BP in diabetic rats, independent of cholesterol.
Why the study?
It was unclear whether the cardiovascular benefits of statins in diabetic subjects are drug-specific or class-dependent and the mechanisms involved.
Do atorvastatin, simvastatin, and pravastatin equally improve cardiovascular performance in diabetic rats?
Do atorvastatin, simvastatin, and pravastatin equally improve cardiovascular performance in diabetic rats?
Low-dose atorvastatin, simvastatin, and pravastatin equally improve cardiovascular performance and endothelial function in diabetic rats through cholesterol-independent, antioxidant mechanisms.
Answers are grounded in this paper and cite their sources.
Equal CV benefits across statins in diabetic rats support class effect; leaves open translation to human diabetes outcomes.
AIM: To investigate if the effect of statins improving cardiovascular (CV) status of diabetics is drug-specific or class-dependent, and the underlying mechanisms involved. METHODS: We compared the results of daily administration over a four-week period of a low dose (10 mg/kg per day) of atorvastatin (AV), simvastatin (SV), and pravastatin (PV) on cardiac performance in diabetic rats. Echocardiographic variables were tested, as well as systolic blood pressure (SBP), acetylcholine (ACh)-induced relaxation, plasma cholesterol levels, and perivascular fibrosis. Malondialdehyde (MDA) and 4-hydroxyalkenal (4-HAE), and endothelial nitric oxide synthase (eNOS) and inducible nitric oxide synthase (iNOS) protein levels were also measured in cardiac and aortic homogenates. RESULTS: In untreated diabetic rats, cholesterol levels were higher than in control rats (CT; n = 8, P < 0.05), and the low dose of statins used did not modify these levels. In diabetic rats, SBP was higher than in CT, and was significantly reduced by all three statins (n = 10, P < 0.05). Echocardiographic parameters (EF, SV, and COI) were all lower in untreated diabetic rats than in CT (n = 10, P < 0.05). These CV parameters were equally improved by all three statins. The maximal relaxation (EMax) induced by ACh in aortic ring from diabetic rats was also improved. Moreover, this relaxation was abolished by 1 mmol/L NG-nitro-L-arginine methyl ester, suggesting the involvement of a NO-dependent mechanism. CONCLUSION: AV, SV, and PV are equally effective in improving CV performance in diabetic rats. All tree statins decreased media thickness, perivascular fibrosis, and both MDA and 4-HAE in the aortas of diabetic rats, without affecting eNOS and iNOS protein levels. The observed hemodynamic benefits are cholesterol-independent. These benefits appear to be secondary to the improved endothelial function, and to the reduced vascular tone and remodeling that result from decreased oxidative stress.
No takes yet. Share an insight, caveat, or question.
María J. Crespo (2015) studied Diabetes (in rats). Atorvastatin, simvastatin, and pravastatin vs. Untreated diabetic rats and control rats was evaluated on Cardiac performance (EF, SV, and COI) and systolic blood pressure (p=<0.05). Atorvastatin, simvastatin, and pravastatin equally improved cardiovascular performance and reduced systolic blood pressure in diabetic rats (P<0.05), independent of cholesterol levels.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: